Smartphone ECG with AI could spot hidden heart disease in families

NCT ID NCT06609174

Completed Diagnosis Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tested whether a portable 6-lead ECG device, paired with an artificial intelligence algorithm, can help screen first-degree relatives of people with dilated cardiomyopathy (a weakened heart muscle). The goal was to see if this mobile approach could detect reduced heart function early. The study enrolled 119 participants and measured how many relatives completed the screening and how many had a low ejection fraction (≤45%).

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: KardiaRx 6-lead ECG device with AI interpretation
What this could lead to: If successful, this approach could make it easier and more accessible to screen at-risk family members for early signs of heart muscle disease.
What could go wrong: This is a small pilot study with only 119 participants, so results may not apply to everyone. The AI algorithm's accuracy in detecting reduced heart function needs further validation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOMYOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiomyopathy dilated cardiomyopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIOMYOPATHY

Contacts and locations

Locations

Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.